Yan Chen

发表

Novel multi-kinase inhibitor, T03 inhibits Taxol-resistant breast cancer

Y. Li, Jindong Chen, Chunxia Liu, 2017, Molecular medicine reports.

Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

Matthew D. Shirley, Hao Wang, P. Hammerman, 2021, Cancer Research.

Single-vector inducible lentiviral RNAi system for oncology target validation

J. D. Benson, W. Sellers, G. Caponigro, 2009, Cell cycle.

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Angela Tam, Manway Liu, J. Baselga, 2015, Cancer cell.

An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.

W. Sellers, J. Gu, C. Arteaga, 2013, Cancer research.

Identification of cervical cancer markers by cDNA and tissue microarrays.

David Yang, Frank Cronin, Michael P. Morrissey, 2003, Cancer research.

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

J. Lehár, Manway Liu, R. Schlegel, 2014, Cancer cell.

Functional silencing of hepatic microsomal glucose‐6‐phosphatase gene expression in vivo by adenovirus‐mediated delivery of short hairpin RNA

D. White, Shanchuan Zhao, Yan Chen, 2004, FEBS letters.

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

M. Lawrence, G. Caponigro, J. Engelman, 2018, Nature Medicine.

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis.

J. Zhao, W. Zhong, Mengzhao Wang, 2013, Lung cancer.

RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth

J. Lehár, Anupama Reddy, P. Finan, 2012, PloS one.

Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab.

R. Schlegel, M. Peters, M. Pinzon-Ortiz, 2013 .

Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers

P. Hammerman, G. Dranoff, J. Engelman, 2018, Clinical research.

Abstract 2733: LJM716: an anti-HER3 antibody that inhibits both HER2 and NRG driven tumor growth by trapping HER3 in the inactive conformation.

Dongshu Chen, Q. Sheng, S. Ettenberg, 2012 .